Petros Pharmaceuticals (Nasdaq:PTPI) - Stock Price, News & Analysis

PTPI Stock Overview

Petros Pharmaceuticals, Inc. es una empresa farmacéutica centrada en la terapéutica de la salud masculina en Estados Unidos y a escala internacional.

About the company

PTPI fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Cotiza un 99.2% por debajo de nuestra estimación de su valor razonable

Se prevé un crecimiento anual de los ingresos de 30.72%

Los beneficios han crecido 17.9% al año en los últimos 5 años.

Trading a buen valor en comparación con empresas similares e industria

Risk Analysis

No tiene una capitalización bursátil significativa ($3M)

Los accionistas se han diluido en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Volatilidad del precio de la acción en los últimos 3 meses

Petros Pharmaceuticals, Inc. Competitors

cbdMD

NYSEAM:YCBD

US$2.7m

Sonoma Pharmaceuticals

NasdaqCM:SNOA

US$2.5m

China Pharma Holdings

NYSEAM:CPHI

US$4.1m

Pulmatrix

NasdaqCM:PULM

US$6.6m

Price History & Performance

Summary of all time highs, changes and price drops for Petros Pharmaceuticals
Historical stock prices
Current Share Price	US$0.93
52 Week High	US$9.54
52 Week Low	US$0.90
Beta	2.28
1 Month Change	-42.94%
3 Month Change	-34.54%
1 Year Change	-5.10%
3 Year Change	-97.22%
5 Year Change	n/a
Change since IPO	-97.67%

Recent updates

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Aug 15

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Jul 28

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Dec 07

Shareholder Returns

	PTPI	US Pharmaceuticals	US Market
7D	-35.9%	0.3%	-0.2%
1Y	-5.1%	20.4%	25.7%

Rentabilidad frente al sector: PTPI obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 20.2%.

Rentabilidad vs. Mercado: PTPI obtuvo unos resultados inferiores a los del mercado US, que fue del 22.3% el año pasado.

Price Volatility

Is PTPI's price volatile compared to industry and market?
PTPI volatility
PTPI Average Weekly Movement	16.1%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.9%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de PTPI ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: PTPIha disminuido de 55% a 16% en el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
n/a	24	n/a	https://www.petrospharma.com

Petros Pharmaceuticals, Inc. es una empresa farmacéutica centrada en la terapéutica de la salud masculina en Estados Unidos y a escala internacional. Opera a través de dos segmentos, Medicamentos de Prescripción y Dispositivos Médicos. La empresa se dedica a la comercialización y el desarrollo de Stendra, un medicamento de venta con receta inhibidor de la PDE-5 para el tratamiento de la disfunción eréctil (DE).

Petros Pharmaceuticals, Inc. Fundamentals Summary

How do Petros Pharmaceuticals's earnings and revenue compare to its market cap?
PTPI fundamental statistics
Market cap	US$2.05m
Earnings (TTM)	-US$13.81m
Revenue (TTM)	US$5.82m

0.4x

P/S Ratio

-0.1x

P/E Ratio

Is PTPI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTPI income statement (TTM)
Revenue	US$5.82m
Cost of Revenue	US$1.63m
Gross Profit	US$4.19m
Other Expenses	US$18.01m
Earnings	-US$13.81m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-6.28
Gross Margin	71.98%
Net Profit Margin	-237.26%
Debt/Equity Ratio	64.2%

How did PTPI perform over the long term?

See historical performance and comparison

PTPI Stock Overview

Rewards

Risk Analysis

Petros Pharmaceuticals, Inc. Competitors

NYSEAM:YCBD

US$2.7m

NasdaqCM:SNOA

US$2.5m

NYSEAM:CPHI

US$4.1m

NasdaqCM:PULM

US$6.6m

Price History & Performance

Recent News & Updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Recent updates

Full year 2023 earnings: EPS and revenues miss analyst expectations

Petros Pharmaceuticals, Inc. Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA (avanafil) as it Pursues OTC Status

Insufficient new directors

Petros Pharmaceuticals, Inc. Announces Successful Completion of the Initial Cohort of A Phase 2 Equivalent Self-Selection Study

Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status

Petros Pharmaceuticals, Inc., Annual General Meeting, Dec 29, 2023

Petros Pharmaceuticals, Inc. announced delayed 10-Q filing

Petros Pharmaceuticals Announces to Develop Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

Petros Pharmaceuticals, Inc. Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential Otc Stendra Label

Second quarter 2023 earnings released: US$1.20 loss per share (vs US$0.88 loss in 2Q 2022)

Petros Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.084 loss in 1Q 2022)

Third quarter 2022 earnings released: US$0.67 loss per share (vs US$0.17 loss in 3Q 2021)

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Expansion of FDA Labeling for Its Oral Erectile Dysfunction Drug, STENDRA

Petros Pharmaceuticals, Inc., Annual General Meeting, Nov 29, 2022

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Second quarter 2022 earnings released: US$0.088 loss per share (vs US$0.22 loss in 2Q 2021)

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Petros Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.008 loss per share (vs US$0.31 profit in 1Q 2021)

Petros Pharmaceuticals, Inc. Announces They Will Be Pursuing the 505(B)(2) Pathway for Its Investigational Agent

High number of new and inexperienced directors

Petros Pharmaceuticals, Inc. Announces Positive Results of Over-The-Counter (Otc) Label Comprehension Study for Erectile Dysfunction Drug STENDRA

Full year 2021 earnings released: US$0.82 loss per share (vs US$3.86 loss in FY 2020)

Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug Stendra (Avanafil)

Petros Pharmaceuticals, Inc. announced that it has received $2.200023 million in funding

Petros Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.299978 million.

Petros Pharmaceuticals, Inc. announced that it expects to receive $2.200023 million in funding

Petros Pharmaceuticals Announces Positive Over-the-Counter Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.96 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.22 loss per share (vs US$1.68 loss in 2Q 2020)

Petros Pharmaceuticals, Inc. Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment

Petros Pharmaceuticals, Inc.(NasdaqCM:PTPI) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: EPS US$0.31 (vs US$1.77 loss in 1Q 2020)

New 90-day low: US$3.22

Petros Pharmaceuticals Appoints Dr. Mohit Khera to Steering Committee

Petros Pharmaceuticals, Inc. Appoints Mitchell Arnold to Serve as the Principal Financial Officer and Principal Accounting Officer

Petros Pharmaceuticals, Inc. Announces Executive Changes